PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 206 filers reported holding PDL BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is 0.15 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,659,000 | -11.8% | 843,988 | -18.6% | 0.00% | -50.0% |
| Q2 2020 | $3,016,000 | +284.2% | 1,036,280 | +272.5% | 0.00% | +100.0% |
| Q1 2020 | $785,000 | -13.1% | 278,222 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $903,000 | +50.2% | 278,222 | 0.0% | 0.00% | – |
| Q3 2019 | $601,000 | -29.3% | 278,222 | +2.8% | 0.00% | -100.0% |
| Q2 2019 | $850,000 | -61.6% | 270,722 | -54.5% | 0.00% | 0.0% |
| Q1 2019 | $2,214,000 | +62.8% | 595,194 | +26.9% | 0.00% | 0.0% |
| Q4 2018 | $1,360,000 | +69.2% | 468,956 | +53.5% | 0.00% | 0.0% |
| Q3 2018 | $804,000 | +12.4% | 305,522 | 0.0% | 0.00% | – |
| Q2 2018 | $715,000 | -7.3% | 305,522 | +16.5% | 0.00% | -100.0% |
| Q1 2018 | $771,000 | +12.9% | 262,322 | +5.3% | 0.00% | – |
| Q4 2017 | $683,000 | -19.2% | 249,222 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $845,000 | +24.3% | 249,222 | -9.5% | 0.00% | 0.0% |
| Q2 2017 | $680,000 | +16.4% | 275,422 | +7.0% | 0.00% | – |
| Q1 2017 | $584,000 | +7.0% | 257,322 | 0.0% | 0.00% | – |
| Q4 2016 | $546,000 | -45.6% | 257,322 | -14.1% | 0.00% | -100.0% |
| Q3 2016 | $1,004,000 | +6.7% | 299,722 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $941,000 | -5.7% | 299,722 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $998,000 | -5.9% | 299,722 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $1,061,000 | -29.6% | 299,722 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $1,508,000 | -21.8% | 299,722 | -0.1% | 0.00% | -50.0% |
| Q2 2015 | $1,929,000 | -17.4% | 299,962 | -9.6% | 0.00% | 0.0% |
| Q1 2015 | $2,334,000 | -8.8% | 331,765 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $2,558,000 | +3.2% | 331,765 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $2,478,000 | -22.8% | 331,765 | 0.0% | 0.00% | -33.3% |
| Q2 2014 | $3,211,000 | +35.5% | 331,765 | +16.4% | 0.00% | +50.0% |
| Q1 2014 | $2,369,000 | -1.6% | 285,065 | -0.0% | 0.00% | 0.0% |
| Q4 2013 | $2,407,000 | -0.2% | 285,207 | -5.8% | 0.00% | 0.0% |
| Q3 2013 | $2,413,000 | +2.6% | 302,785 | -0.6% | 0.00% | 0.0% |
| Q2 2013 | $2,352,000 | – | 304,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |